Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...
The Motley Fool19d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
But the real excitement lies in Vertex's push beyond CF, where years of investment are finally bearing fruit. All eyes are on Jan. 30, when the FDA weighs in on suzetrigine -- a potential game ...
Vertex wins FDA approval for long-awaited non-opioid painkiller
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
Yahoo Finance3d
Vertex Pharmaceuticals Incorporated (VRTX)
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX ... Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.